← boardnext 2027-01
CPIX
Cumberland Pharmaceuticalsdistress 0/10 · well-funded / low risk$6.83-4%today-13% from 52w high
Immunology / Inflammation 1
Lead: Scleroderma
Revenue
pre-revenue
Liquidity
$11M
Runway
—
Shares 1y
+0%
Price & events
+69.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.1%
1D
-10.8%
1W
+17.2%
1M
+75.1%
3M
+73.8%
6M
+91.9%
1Y
+355.3%
2Y
+109.5%
5Y
+128.4%
All
Overview
- Market Cap
- $102.33M
- Volume
- 45.20K
- 52 Week Range
- $1.90 – $7.85
- Total Shares
- 14.98M
- Float Shares
- 8.75M
- Short %
- 2.77%
- % Held by Insiders
- 41.60%
- % Held by Institutions
- 18.65%
- RVOL
- 0.57x
- Beta
- 0.10
Pipeline stages · 1 programs
Ifetroban Sodium
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | Ifetroban Sodiumfast trackorphanrare pediatric | Idiopathic Pulmonary Fibrosis | — | recruiting |
| 2026-06 | Phase 2 | Oral Ifetroban, Oral Placebofast trackorphanrare pediatric | Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases | 34 | active not recruiting |
Catalyst news & presentations · 7
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-01partnershipClosed asset sale of commercial products to Apotex for $100MSEC 8-K
- 2026-04-22partnershipAcetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ · Entered into asset purchase agreement with Apotex to sell these FDA-approved products for $100 million.SEC 8-K
- 2025-10-20partnershipTalicia · Strategic arrangement with RedHill Biopharma to jointly commercialize Talicia for H. pylori infectionSEC 8-K
- 2025-02-18partnershipVibativ (telavancin) · SciClone granted exclusive rights to register, promote, and distribute Vibativ in ChinaSEC 8-K
- February 4, 2025readoutPhase 2ifetroban · Positive top-line results from Phase 2 FIGHT DMD trial.SEC 8-K
- later this yearreadoutPhase 2Ifetroban · Topline results from FIGHT DMD Phase 2 trialSEC 8-K
Approved drugs (7)
- OMECLAMOX-PAKAMOXICILLIN2011 · Discontinued
- VIBATIVTELAVANCIN HYDROCHLORIDE2009 · Discontinued
- CALDOLORIBUPROFEN2009 · Prescription
- SANCUSOGRANISETRON2008 · Prescription
- VAPRISOLCONIVAPTAN HYDROCHLORIDE2007 · Prescription
- VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINERCONIVAPTAN HYDROCHLORIDE2005 · Prescription
- ACETADOTEACETYLCYSTEINE2004 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Scleroderma
Recent news
- 2026-07-18Cumberland Pharmaceuticals declares $1.50 dividend - MSN
- 2026-07-15Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX - Moomoo
- 2026-07-15ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - The Globe and Mail
- 2026-07-15ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - Yahoo Finance
- 2026-07-15ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - TradingView
- 2026-07-15ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - Zacks Investment Research
- 2026-07-14BRIEF-Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share - Dailyhunt
- 2026-07-14Cumberland Pharmaceuticals declares $1.50 dividend - MSN
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.